CA2704190A1 - Compositions de nell-1 - Google Patents

Compositions de nell-1 Download PDF

Info

Publication number: CA2704190A1
Authority: CA; Canada
Prior art keywords: nell; protein; composition; bone; cartilage
Prior art date: 2007-10-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2704190A

Other languages

English (en)

Inventor

Kang Ting

Chia Soo

Xinli Zhang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of California San Diego UCSD

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-30

Filing date

2008-10-24

Publication date

2009-05-07

2008-10-24 Application filed by Individual filed Critical Individual

2009-05-07 Publication of CA2704190A1 publication Critical patent/CA2704190A1/fr

Status Abandoned legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 67
108090000623 proteins and genes Proteins 0.000 claims abstract description 118
102000004169 proteins and genes Human genes 0.000 claims abstract description 99
230000033115 angiogenesis Effects 0.000 claims abstract description 46
238000000034 method Methods 0.000 claims abstract description 43
210000001519 tissue Anatomy 0.000 claims description 45
230000011164 ossification Effects 0.000 claims description 33
230000015572 biosynthetic process Effects 0.000 claims description 26
230000022159 cartilage development Effects 0.000 claims description 26
230000001772 anti-angiogenic effect Effects 0.000 claims description 25
230000000259 anti-tumor effect Effects 0.000 claims description 18
230000002491 angiogenic effect Effects 0.000 claims description 17
230000002401 inhibitory effect Effects 0.000 claims description 13
230000003190 augmentative effect Effects 0.000 claims description 12
230000002792 vascular Effects 0.000 claims description 11
230000001737 promoting effect Effects 0.000 claims description 9
230000000118 anti-neoplastic effect Effects 0.000 claims description 6
230000002708 enhancing effect Effects 0.000 claims description 5
230000001093 anti-cancer Effects 0.000 claims description 2
230000003527 anti-angiogenesis Effects 0.000 abstract description 7
210000001612 chondrocyte Anatomy 0.000 description 68
210000000988 bone and bone Anatomy 0.000 description 54
210000004027 cell Anatomy 0.000 description 53
108090000765 processed proteins & peptides Proteins 0.000 description 53
210000000845 cartilage Anatomy 0.000 description 45
239000000463 material Substances 0.000 description 32
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 30
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 30
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 30
108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 26
230000014509 gene expression Effects 0.000 description 25
102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 24
238000010186 staining Methods 0.000 description 21
108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 18
102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 18
238000012384 transportation and delivery Methods 0.000 description 18
108010046722 Thrombospondin 1 Proteins 0.000 description 17
102100036034 Thrombospondin-1 Human genes 0.000 description 17
229940112869 bone morphogenetic protein Drugs 0.000 description 17
238000002347 injection Methods 0.000 description 16
239000007924 injection Substances 0.000 description 16
238000010361 transduction Methods 0.000 description 16
230000006870 function Effects 0.000 description 15
230000026683 transduction Effects 0.000 description 15
241000283707 Capra Species 0.000 description 14
210000003559 hypertrophic chondrocyte Anatomy 0.000 description 14
238000001727 in vivo Methods 0.000 description 14
206010028980 Neoplasm Diseases 0.000 description 13
230000035194 endochondral ossification Effects 0.000 description 13
230000012010 growth Effects 0.000 description 13
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 12
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 12
239000000126 substance Substances 0.000 description 12
229920002971 Heparan sulfate Polymers 0.000 description 11
238000009739 binding Methods 0.000 description 11
210000004204 blood vessel Anatomy 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
210000002744 extracellular matrix Anatomy 0.000 description 11
230000004048 modification Effects 0.000 description 11
238000012986 modification Methods 0.000 description 11
-1 poly(ethylene glycol) Polymers 0.000 description 11
230000008569 process Effects 0.000 description 11
230000008439 repair process Effects 0.000 description 11
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 10
230000004069 differentiation Effects 0.000 description 10
230000000694 effects Effects 0.000 description 10
230000001965 increasing effect Effects 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 9
230000002648 chondrogenic effect Effects 0.000 description 9
230000007547 defect Effects 0.000 description 9
239000003550 marker Substances 0.000 description 9
150000001875 compounds Chemical class 0.000 description 8
230000009545 invasion Effects 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
239000003981 vehicle Substances 0.000 description 8
108010035532 Collagen Proteins 0.000 description 7
102000008186 Collagen Human genes 0.000 description 7
229920001436 collagen Polymers 0.000 description 7
239000012634 fragment Substances 0.000 description 7
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
241000699660 Mus musculus Species 0.000 description 6
208000027418 Wounds and injury Diseases 0.000 description 6
238000003364 immunohistochemistry Methods 0.000 description 6
230000003993 interaction Effects 0.000 description 6
210000000963 osteoblast Anatomy 0.000 description 6
230000037361 pathway Effects 0.000 description 6
229920000642 polymer Polymers 0.000 description 6
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
102000016289 Cell Adhesion Molecules Human genes 0.000 description 5
108010067225 Cell Adhesion Molecules Proteins 0.000 description 5
206010017076 Fracture Diseases 0.000 description 5
241000282414 Homo sapiens Species 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
102000004067 Osteocalcin Human genes 0.000 description 5
108090000573 Osteocalcin Proteins 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
206010003246 arthritis Diseases 0.000 description 5
210000001188 articular cartilage Anatomy 0.000 description 5
239000000919 ceramic Substances 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
208000029078 coronary artery disease Diseases 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
239000003937 drug carrier Substances 0.000 description 5
230000003328 fibroblastic effect Effects 0.000 description 5
238000009472 formulation Methods 0.000 description 5
229920000669 heparin Polymers 0.000 description 5
229960002897 heparin Drugs 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000000921 morphogenic effect Effects 0.000 description 5
238000011580 nude mouse model Methods 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000012546 transfer Methods 0.000 description 5
208000010392 Bone Fractures Diseases 0.000 description 4
108010022510 Collagen Type X Proteins 0.000 description 4
102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 4
108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 4
102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
102000043136 MAP kinase family Human genes 0.000 description 4
108091054455 MAP kinase family Proteins 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
208000001132 Osteoporosis Diseases 0.000 description 4
108010067787 Proteoglycans Proteins 0.000 description 4
102000016611 Proteoglycans Human genes 0.000 description 4
206010052428 Wound Diseases 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
230000003466 anti-cipated effect Effects 0.000 description 4
238000013459 approach Methods 0.000 description 4
230000011227 chondrocyte hypertrophy Effects 0.000 description 4
238000009833 condensation Methods 0.000 description 4
230000005494 condensation Effects 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000001415 gene therapy Methods 0.000 description 4
239000003102 growth factor Substances 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
230000001969 hypertrophic effect Effects 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
150000007523 nucleic acids Chemical class 0.000 description 4
210000004940 nucleus Anatomy 0.000 description 4
230000002188 osteogenic effect Effects 0.000 description 4
238000007634 remodeling Methods 0.000 description 4
230000011664 signaling Effects 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
239000000758 substrate Substances 0.000 description 4
238000005670 sulfation reaction Methods 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
239000013598 vector Substances 0.000 description 4
102000030746 Collagen Type X Human genes 0.000 description 3
102000015225 Connective Tissue Growth Factor Human genes 0.000 description 3
108010039419 Connective Tissue Growth Factor Proteins 0.000 description 3
208000009283 Craniosynostoses Diseases 0.000 description 3
206010049889 Craniosynostosis Diseases 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
239000004037 angiogenesis inhibitor Substances 0.000 description 3
239000003080 antimitotic agent Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000033558 biomineral tissue development Effects 0.000 description 3
210000002805 bone matrix Anatomy 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
230000008859 change Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
210000003541 chondroclast Anatomy 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
230000029087 digestion Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
210000004728 ear cartilage Anatomy 0.000 description 3
238000006345 epimerization reaction Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
208000014674 injury Diseases 0.000 description 3
239000003446 ligand Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
238000010603 microCT Methods 0.000 description 3
230000014399 negative regulation of angiogenesis Effects 0.000 description 3
210000005009 osteogenic cell Anatomy 0.000 description 3
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 3
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
239000000843 powder Substances 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
230000007115 recruitment Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
239000000523 sample Substances 0.000 description 3
230000017423 tissue regeneration Effects 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
230000003827 upregulation Effects 0.000 description 3
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
208000007342 Diabetic Nephropathies Diseases 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
241001269524 Dura Species 0.000 description 2
102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
229920002683 Glycosaminoglycan Polymers 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
206010020880 Hypertrophy Diseases 0.000 description 2
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
102000019145 JUN kinase activity proteins Human genes 0.000 description 2
102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
AMFGWXWBFGVCKG-UHFFFAOYSA-N Panavia opaque Chemical compound C1=CC(OCC(O)COC(=O)C(=C)C)=CC=C1C(C)(C)C1=CC=C(OCC(O)COC(=O)C(C)=C)C=C1 AMFGWXWBFGVCKG-UHFFFAOYSA-N 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
102000013275 Somatomedins Human genes 0.000 description 2
102000007000 Tenascin Human genes 0.000 description 2
108010008125 Tenascin Proteins 0.000 description 2
102000002938 Thrombospondin Human genes 0.000 description 2
108060008245 Thrombospondin Proteins 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
230000001668 ameliorated effect Effects 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000012867 bioactive agent Substances 0.000 description 2
239000005313 bioactive glass Substances 0.000 description 2
230000014461 bone development Effects 0.000 description 2
230000008468 bone growth Effects 0.000 description 2
210000002798 bone marrow cell Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000005907 cancer growth Effects 0.000 description 2
230000003848 cartilage regeneration Effects 0.000 description 2
230000011712 cell development Effects 0.000 description 2
230000003915 cell function Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000005754 cellular signaling Effects 0.000 description 2
239000004568 cement Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
208000033679 diabetic kidney disease Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
210000002308 embryonic cell Anatomy 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
229940097043 glucuronic acid Drugs 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
239000008187 granular material Substances 0.000 description 2
210000004349 growth plate Anatomy 0.000 description 2
210000003128 head Anatomy 0.000 description 2
239000000017 hydrogel Substances 0.000 description 2
229910052588 hydroxylapatite Inorganic materials 0.000 description 2
238000013388 immunohistochemistry analysis Methods 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
238000002513 implantation Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
230000032631 intramembranous ossification Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000011707 mineral Substances 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
230000001089 mineralizing effect Effects 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
230000006320 pegylation Effects 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
229920001992 poloxamer 407 Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
230000026341 positive regulation of angiogenesis Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000001023 pro-angiogenic effect Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
231100001055 skeletal defect Toxicity 0.000 description 2
239000002904 solvent Substances 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
108010020352 tenascin X Proteins 0.000 description 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
230000009772 tissue formation Effects 0.000 description 2
208000037816 tissue injury Diseases 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
239000013638 trimer Substances 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
230000009790 vascular invasion Effects 0.000 description 2
238000012800 visualization Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
238000001262 western blot Methods 0.000 description 2
238000002424 x-ray crystallography Methods 0.000 description 2
WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
HBAHZZVIEFRTEY-UHFFFAOYSA-N 2-heptylcyclohex-2-en-1-one Chemical compound CCCCCCCC1=CCCCC1=O HBAHZZVIEFRTEY-UHFFFAOYSA-N 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
108010067219 Aggrecans Proteins 0.000 description 1
102000016284 Aggrecans Human genes 0.000 description 1
102000009840 Angiopoietins Human genes 0.000 description 1
108010009906 Angiopoietins Proteins 0.000 description 1
102400000068 Angiostatin Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
102000004411 Antithrombin III Human genes 0.000 description 1
108090000935 Antithrombin III Proteins 0.000 description 1
238000011729 BALB/c nude mouse Methods 0.000 description 1
239000004342 Benzoyl peroxide Substances 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
235000014653 Carica parviflora Nutrition 0.000 description 1
241000283153 Cetacea Species 0.000 description 1
241000288673 Chiroptera Species 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
206010061762 Chondropathy Diseases 0.000 description 1
102100031186 Chromogranin-A Human genes 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
241000243321 Cnidaria Species 0.000 description 1
241000209205 Coix Species 0.000 description 1
102000000503 Collagen Type II Human genes 0.000 description 1
108010041390 Collagen Type II Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
108010066259 Collagraft Proteins 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
208000009328 Dentinogenesis Imperfecta Diseases 0.000 description 1
229920000045 Dermatan sulfate Polymers 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
102400001047 Endostatin Human genes 0.000 description 1
108010079505 Endostatins Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
108010090254 Growth Differentiation Factor 5 Proteins 0.000 description 1
102100035379 Growth/differentiation factor 5 Human genes 0.000 description 1
108090000031 Hedgehog Proteins Proteins 0.000 description 1
102000003693 Hedgehog Proteins Human genes 0.000 description 1
101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 1
101001047085 Homo sapiens Kielin/chordin-like protein Proteins 0.000 description 1
101000979284 Homo sapiens Protein kinase C-binding protein NELL1 Proteins 0.000 description 1
101000995264 Homo sapiens Protein kinase C-binding protein NELL2 Proteins 0.000 description 1
101000674717 Homo sapiens Transcription initiation factor TFIID subunit 7-like Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102100022808 Kielin/chordin-like protein Human genes 0.000 description 1
208000035752 Live birth Diseases 0.000 description 1
102000019149 MAP kinase activity proteins Human genes 0.000 description 1
108040008097 MAP kinase activity proteins Proteins 0.000 description 1
108010072582 Matrilin Proteins Proteins 0.000 description 1
102000055008 Matrilin Proteins Human genes 0.000 description 1
229920001367 Merrifield resin Polymers 0.000 description 1
102000002111 Neuropilin Human genes 0.000 description 1
108050009450 Neuropilin Proteins 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
102000004211 Platelet factor 4 Human genes 0.000 description 1
108090000778 Platelet factor 4 Proteins 0.000 description 1
229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
102100034433 Protein kinase C-binding protein NELL2 Human genes 0.000 description 1
230000010799 Receptor Interactions Effects 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
241000219061 Rheum Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
208000002847 Surgical Wound Diseases 0.000 description 1
102100021172 Transcription initiation factor TFIID subunit 7-like Human genes 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
108010031318 Vitronectin Proteins 0.000 description 1
102100035140 Vitronectin Human genes 0.000 description 1
101001047124 Xenopus laevis Kielin/chordin-like protein Proteins 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
238000000137 annealing Methods 0.000 description 1
229910052661 anorthite Inorganic materials 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
229960005348 antithrombin iii Drugs 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
238000007630 basic procedure Methods 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
235000019400 benzoyl peroxide Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000003462 bioceramic Substances 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
239000012620 biological material Substances 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000007698 birth defect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000002639 bone cement Substances 0.000 description 1
230000018678 bone mineralization Effects 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000000648 calcium alginate Substances 0.000 description 1
235000010410 calcium alginate Nutrition 0.000 description 1
229960002681 calcium alginate Drugs 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
229910001634 calcium fluoride Inorganic materials 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000008568 cell cell communication Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000008619 cell matrix interaction Effects 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
230000009816 chondrogenic differentiation Effects 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
102000006533 chordin Human genes 0.000 description 1
108010008846 chordin Proteins 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000006854 communication Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
239000000805 composite resin Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229910052878 cordierite Inorganic materials 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000008226 craniofacial development Effects 0.000 description 1
238000003381 deacetylation reaction Methods 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000032459 dedifferentiation Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
229940051593 dermatan sulfate Drugs 0.000 description 1
GWWPLLOVYSCJIO-UHFFFAOYSA-N dialuminum;calcium;disilicate Chemical compound [Al+3].[Al+3].[Ca+2].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] GWWPLLOVYSCJIO-UHFFFAOYSA-N 0.000 description 1
230000009699 differential effect Effects 0.000 description 1
JSKIRARMQDRGJZ-UHFFFAOYSA-N dimagnesium dioxido-bis[(1-oxido-3-oxo-2,4,6,8,9-pentaoxa-1,3-disila-5,7-dialuminabicyclo[3.3.1]nonan-7-yl)oxy]silane Chemical compound [Mg++].[Mg++].[O-][Si]([O-])(O[Al]1O[Al]2O[Si](=O)O[Si]([O-])(O1)O2)O[Al]1O[Al]2O[Si](=O)O[Si]([O-])(O1)O2 JSKIRARMQDRGJZ-UHFFFAOYSA-N 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
210000001162 elastic cartilage Anatomy 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000004578 fetal growth Effects 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
210000000968 fibrocartilage Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229910052587 fluorapatite Inorganic materials 0.000 description 1
229940077441 fluorapatite Drugs 0.000 description 1
210000001650 focal adhesion Anatomy 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
230000007045 gastrulation Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
238000003633 gene expression assay Methods 0.000 description 1
238000002695 general anesthesia Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000002241 glass-ceramic Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
208000035474 group of disease Diseases 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
230000010370 hearing loss Effects 0.000 description 1
231100000888 hearing loss Toxicity 0.000 description 1
208000016354 hearing loss disease Diseases 0.000 description 1
102000045896 human BMP2 Human genes 0.000 description 1
102000046107 human BMP7 Human genes 0.000 description 1
102000053009 human NELL1 Human genes 0.000 description 1
210000003035 hyaline cartilage Anatomy 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
125000001183 hydrocarbyl group Chemical group 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000002991 immunohistochemical analysis Methods 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000005470 impregnation Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000003999 initiator Substances 0.000 description 1
230000008611 intercellular interaction Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
239000010410 layer Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004359 mandibular condyle Anatomy 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000009245 menopause Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000002557 mineral fiber Substances 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
238000007479 molecular analysis Methods 0.000 description 1
238000004264 monolayer culture Methods 0.000 description 1
230000001002 morphogenetic effect Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
CVPJXKJISAFJDU-UHFFFAOYSA-A nonacalcium;magnesium;hydrogen phosphate;iron(2+);hexaphosphate Chemical compound [Mg+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Fe+2].OP([O-])([O-])=O.OP([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O CVPJXKJISAFJDU-UHFFFAOYSA-A 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000009818 osteogenic differentiation Effects 0.000 description 1
230000004819 osteoinduction Effects 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000035699 permeability Effects 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
239000008196 pharmacological composition Substances 0.000 description 1
229910052628 phlogopite Inorganic materials 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000002243 precursor Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
238000000751 protein extraction Methods 0.000 description 1
230000012846 protein folding Effects 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000006432 protein unfolding Effects 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000012827 research and development Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
201000004193 respiratory failure Diseases 0.000 description 1
230000004044 response Effects 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000037390 scarring Effects 0.000 description 1
230000037387 scars Effects 0.000 description 1
206010039722 scoliosis Diseases 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
238000004088 simulation Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000002639 sodium chloride Nutrition 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
238000012549 training Methods 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
229940078499 tricalcium phosphate Drugs 0.000 description 1
229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
108010060757 vasostatin Proteins 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229910052591 whitlockite Inorganic materials 0.000 description 1
239000010456 wollastonite Substances 0.000 description 1
229910052882 wollastonite Inorganic materials 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Orthopedic Medicine & Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA2704190A 2007-10-30 2008-10-24 Compositions de nell-1 Abandoned CA2704190A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US98390307P	2007-10-30	2007-10-30
US60/983,903		2007-10-30
PCT/US2008/081168 WO2009058690A2 (fr)	2007-10-30	2008-10-24	Compositions de nell-1

Publications (1)

Publication Number	Publication Date
CA2704190A1 true CA2704190A1 (fr)	2009-05-07

Family

ID=40591716

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2704190A Abandoned CA2704190A1 (fr)	2007-10-30	2008-10-24	Compositions de nell-1

Country Status (3)

Country	Link
EP (1)	EP2214697A4 (fr)
CA (1)	CA2704190A1 (fr)
WO (1)	WO2009058690A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010111421A2 (fr) *	2009-03-25	2010-09-30	The Regents Of The University Of California	Isoforme du peptide nell-1
WO2019210080A1 (fr) *	2018-04-25	2019-10-31	The Regents Of The University Of California	Méthodes et compositions pour troubles du squelette et neurologiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7687462B2 (en) *	1999-10-05	2010-03-30	The Regents Of The University Of California	Composition for promoting cartilage formation or repair comprising a nell gene product and method of treating cartilage-related conditions using such composition
DE602004032107D1 (de) *	2003-02-07	2011-05-19	Univ California	Nell-peptidexpressionssysteme und knochenbildende aktivität des nell-peptids
US20060053503A1 (en) *	2004-07-30	2006-03-09	Ut-Battelle, Llc	Cranial and vertebral defects associated with loss-of-function of Nell
US7833968B2 (en) *	2005-02-16	2010-11-16	The Regents Of The University Of California	Pharmaceutical compositions for treating or preventing bone conditions

2008
- 2008-10-24 WO PCT/US2008/081168 patent/WO2009058690A2/fr not_active Ceased
- 2008-10-24 CA CA2704190A patent/CA2704190A1/fr not_active Abandoned
- 2008-10-24 EP EP08844676A patent/EP2214697A4/fr not_active Withdrawn

Also Published As

Publication number	Publication date
WO2009058690A3 (fr)	2009-09-24
WO2009058690A2 (fr)	2009-05-07
EP2214697A4 (fr)	2011-05-18
EP2214697A2 (fr)	2010-08-11

Publication	Publication Date	Title
US7884066B2 (en)	2011-02-08	NELL-1 enhanced bone mineralization
US10335458B2 (en)	2019-07-02	Pharmaceutical compositions for treating or preventing bone conditions
Greenwald et al.	2001	In vivo modulation of FGF biological activity alters cranial suture fate
Lee et al.	2002	Enhancement of bone healing based on ex vivo gene therapy using human muscle-derived cells expressing bone morphogenetic protein 2
Malemud	1993	The role of growth factors in cartilage metabolism
Fei et al.	2013	Fibroblast growth factor-2, bone homeostasis and fracture repair
JP2007524360A (ja)	2007-08-30	Ｎｅｌｌペプチドの発現系及びｎｅｌｌペプチドの骨形成活性
US20160304573A1 (en)	2016-10-20	Fibromodulin peptide
JP2009502782A (ja)	2009-01-29	硬組織形成を促進するためのタンパク質製剤
Rutherford et al.	2003	Early events: the in vitro conversion of BMP transduced fibroblasts to chondroblasts
CA2704190A1 (fr)	2009-05-07	Compositions de nell-1
CN1371289A (zh)	2002-09-25	使用TGF－β的基因治疗
CN101601858B (zh)	2012-09-19	中期因子蛋白的用途及含该蛋白的医用装置
Trybek et al.	2020	Osteogenic activity of lactoferrin and its application in contemporary dentistry
WO2019246013A1 (fr)	2019-12-26	Peptides pour améliorer la croissance, la réparation et la fonction cellulaire osseuses
KR19990082999A (ko)	1999-11-25	연골 유도를 위한 골유도 단백질과 배화 인자의 조합물의 용도
Dreyer	2020	Effect of recombinant mouse sclerostin proteins on bone formation in vitro and in a murine model of sclerosteosis
Bozo et al.	2019	Ordinary and Activated Bone Substitutes
Tcacencu	2005	Regenerative medicine of the airway cartilage: a morphological and immunohistochemical study with focus on cricoid cartilage defects treated with BMP-2
Tansık	2017	Bioactive Peptide Nanofibers for Bone Tissue Regeneration
Yoshikawa	2006	Possible Roles of Bone Morphogenetic Proteins and Transforming Growth Factor-βs in the Pathogenesis of OPLL and OLF
Celil	2005	Investigation of the signaling pathways that mediate Osterix during osteoblast lineage progression
Patterson	2007	Regenerative matrices for oriented bone growth in craniofacial and dental repair
WO1999034820A1 (fr)	1999-07-15	Nouvelle utilisation de la molecule de hb-gam

Legal Events

Date	Code	Title	Description
2014-09-18	EEER	Examination request	Effective date: 20140908
2018-03-29	FZDE	Dead	Effective date: 20180215